Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective multicenter analysis of causes of death in wild mammals in Southern Germany (2019-2023).

Frontiers in veterinary science·2026
Same author

Haemolymphatic tissues of captive boa constrictor (Boa constrictor): Morphological features in healthy individuals and with boid inclusion body disease.

Developmental and comparative immunology·2024
Same author

[The subanalysis of Rheuma-VOR demonstrates a considerable need for rheumatological care].

Zeitschrift fur Rheumatologie·2024
Same author

Selenium deficiency is associated with polyneuropathy in primary Sjögren's syndrome.

Clinical nutrition ESPEN·2022
Same author

Flow Cytometric Assessment of AKT Signaling in Platelet Activation: An Alternative Diagnostic Tool for Small Volumes of Blood.

Hamostaseologie·2020
Same author

Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement.

European journal of neurology·2020

Related Experiment Video

Updated: Jun 10, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

[Heparin-induced thrombocytopenia].

T Thiele1, K Althaus, A Greinacher

  • 1Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität, Sauerbruchstraße, 17489 Greifswald, Deutschland.

Der Internist
|August 10, 2010
PubMed
Summary

Heparin-induced thrombocytopenia (HIT) is a serious drug reaction causing dangerous clots. Diagnosis involves clinical scores and lab tests, with anticoagulation being the primary treatment for acute cases.

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Context:

  • Heparin-induced thrombocytopenia (HIT) is a life-threatening immune-mediated adverse drug reaction.
  • HIT involves antibodies against platelet factor 4 (PF4)-heparin complexes, leading to platelet activation and thrombosis.
  • It typically emerges 1-2 weeks after heparin initiation, characterized by significant platelet count drop and thromboembolic events.

Purpose:

  • To outline the pathophysiology, clinical presentation, diagnostic criteria, and management strategies for HIT.
  • To differentiate HIT from other causes of thrombocytopenia.
  • To provide guidance on appropriate anticoagulation for patients with acute HIT.

Summary:

  • HIT diagnosis relies on the 4 T's clinical scoring system and laboratory confirmation of PF4/heparin antibodies or functional assays.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Related Experiment Videos

Last Updated: Jun 10, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

  • A low 4 T's score and negative laboratory tests effectively rule out HIT.
  • Acute HIT management necessitates therapeutic anticoagulation with agents like direct thrombin inhibitors (argatroban, bivalirudin) or indirect Factor Xa inhibitors (fondaparinux).

    • Impact:

    • Improved understanding of HIT pathophysiology and diagnosis.
    • Enhanced clinical decision-making for HIT patient management.
    • Reduced morbidity and mortality associated with HIT and its thromboembolic complications.